Galapagos NV (GLPGA) | Financial Analysis & Statements
Galapagos NV | Large-cap | Healthcare
Galapagos NV | Large-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
275.6M
Gross Profit
240.8M
87.35%
Operating Income
-188.3M
-68.33%
Net Income
74.1M
26.88%
Balance Sheet Metrics
Total Assets
4.1B
Total Liabilities
1.2B
Shareholders Equity
2.9B
Debt to Equity
0.43
Cash Flow Metrics
Operating Cash Flow
-300.6M
Free Cash Flow
-402.1M
Revenue & Profitability Trend
Galapagos NV Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 275.6M | 239.7M | 241.2M | 234.4M | 478.1M |
| Cost of Goods Sold | 34.9M | - | 12.1M | 1.6M | 0 |
| Gross Profit | 240.8M | - | 493.2M | 483.2M | 478.1M |
| Operating Expenses | 416.0M | 311.9M | 363.7M | 389.6M | 651.4M |
| Operating Income | -188.3M | -88.3M | -131.1M | -171.6M | -178.6M |
| Pre-tax Income | -3.1M | 5.6M | -70.8M | -119.4M | -309.8M |
| Income Tax | -1.8M | 9.6M | 572.0K | 1.4M | 1.2M |
| Net Income | 74.1M | 211.7M | -218.0M | -103.2M | -305.4M |
| EPS (Diluted) | - | €3.21 | -€3.32 | -€1.58 | -€4.69 |
Income Statement Trend
Galapagos NV Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 3.3B | 3.9B | 4.2B | 4.9B | 5.4B |
| Non-Current Assets | 796.3M | 495.8M | 497.5M | 331.3M | 348.4M |
| Total Assets | 4.1B | 4.4B | 4.7B | 5.2B | 5.7B |
| Liabilities | |||||
| Current Liabilities | 335.1M | 428.2M | 522.5M | 566.5M | 635.3M |
| Non-Current Liabilities | 903.7M | 1.1B | 1.7B | 2.0B | 2.4B |
| Total Liabilities | 1.2B | 1.6B | 2.2B | 2.5B | 3.0B |
| Equity | |||||
| Total Shareholders Equity | 2.9B | 2.8B | 2.5B | 2.6B | 2.7B |
Balance Sheet Composition
Galapagos NV Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 74.1M | 211.7M | -218.0M | -103.2M | -305.4M |
| Operating Cash Flow | -300.6M | -460.4M | -439.5M | -407.1M | -542.3M |
| Investing Activities | |||||
| Capital Expenditures | -16.7M | -16.3M | -26.6M | -54.2M | -42.5M |
| Investing Cash Flow | 256.5M | 57.0M | -1.2B | 544.9M | 802.6M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -4.9M | -5.0M | -1.5M | -3.9M | 22.0M |
| Free Cash Flow | -402.1M | -425.2M | -537.5M | -561.7M | -518.7M |
Cash Flow Trend
Galapagos NV Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
51.71
Forward P/E
-34.06
Price to Book
0.57
Price to Sales
5.45
PEG Ratio
-34.06
Profitability Ratios
Profit Margin
-58.83%
Operating Margin
-211.68%
Return on Equity
-6.36%
Return on Assets
-4.66%
Financial Health
Current Ratio
7.94
Debt to Equity
0.40
Beta
-0.01
Per Share Data
EPS (TTM)
-€2.73
Book Value per Share
€41.74
Revenue per Share
€4.37
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| glpga | 1.6B | 51.71 | 0.57 | -6.36% | -58.83% | 0.40 |
| Aegon | 9.3B | 15.76 | 1.27 | 7.17% | 5.36% | 74.02 |
| Pharming Group N.V | 637.6M | 57.15 | 2.88 | -6.78% | -4.40% | 55.34 |
| Avantium N.V | 113.2M | -35.65 | 1.17 | -43.03% | -127.72% | 144.79 |
| Vivoryon | 39.2M | -1.85 | 4.97 | -120.41% | 0.00% | 1.29 |
| Koninklijke Philips | 18.0B | 74.96 | 1.54 | 1.99% | 2.08% | 64.54 |
Financial data is updated regularly. All figures are in the company's reporting currency.